世界卫生组织初级卫生保健特别方案的评价：报告

Report Evaluation of the WHO Special Programme on Primary Health Care: report ISBN 978-92-4-009665-3 (electronic version)ISBN 978-92-4-009666-0 (print version) © World Health Organization 2025 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGOlicence (CC BY-NC-SA 3.0 IGO;https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided thework is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorsesany specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then youmust license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, youshould add the following disclaimer along with the suggested citation:“This translation was not created by the World HealthOrganization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English editionshall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of theWorld Intellectual Property Organization (http://www.wipo.int/amc/en/mediation/rules/). Suggested citation. Evaluation of the WHO Special Programme on Primary Health Care: report. Geneva: World HealthOrganization; 2025. Licence:CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.CIP data are available athttp://iris.who.int. Sales, rights and licensing.To purchase WHO publications, seehttps://www.who.int/publications/book-orders. To submitrequests for commercial use and queries on rights and licensing, seehttps://www.who.int/copyright. Third-party materials.If you wish to reuse material from this work that is attributed to a third party, such as tables, figuresor images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from thecopyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solelywith the user. General disclaimers.The designations employed and the presentation of the material in this publication do not imply theexpression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area orof its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps representapproximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed orrecommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, thenames of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, thepublished material is being distributed without warranty of any kind, either expressed or implied. The responsibility for theinterpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use. In line with theWHO Evaluation Policy 2018(EB143(9)), this publication contains an independent evaluation report by theWHO Evaluation Office. It does not reflect the views or policies of WHO. WHO/DGO/EVL/2024.1 Cover page photo credit:KENYA: WHO Malaria Vaccine Implementation Programme visit, February 2023, @WHO/FanjanCombrink Contents Acknowledgementsiv 1.Introduc�on2.Evalua�on findings3.Conclusions4.Recommenda�ons List of tablesTable 1: SP-PHC staffing levels by unit as of 15 May 2023–Filled posi�ons 5Table 2: Current SP-PHC ac�vi�es/interven�on areas6Table 3: Scope–Func�ons, workstreams and interven�on areas8Table 4. EQs9Table 5: Number of informants interviewed or par�cipa�ng in focus group discussions, by stakeholder group and level13Table 6. Strength of evidence ra�ng16Table 7. Evalua�on limita�ons and mi�ga�on measure16Table 8. Snapshot of implementa�on on work plans using green, amber and red to denote progress.34Table 9. Responses to online survey ques�on37 List of figuresFig. 1. Timeline representa�on of SP-PHC development, evolu�on and context 4Fig. 2. Posi�oning of the SP-PHC in the WHO headquarters organigram, as of 1 January 20235Fig. 3. Constructed ToC for the SP-PHC with mapped EQs11Fig. 4. Enablers and barriers to applying a PHC approach to HIV responses (32)28Fig. 5. WHO SP-PHC amount budgeted by 2020–2021 and 2022–2023 biennium43Fig. 6. Funding for the UHC-P and the number of countries supported (2012–2026)45Fig. 7. UHC SCI index of 192 countries (latest available data) and overlap with “WHO intensified support countries”50 Acknowledgements This report is issued by the World